We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blocking the Thromboxane Receptor Prevents Alzheimer's Disease in Mouse Model

By LabMedica International staff writers
Posted on 30 Nov 2014
A recent study carried out on a transgenic mouse model of Alzheimer's disease identified the thromboxane receptor (TP) as an active contributor to the development of the disease and a feasible target for drugs to treat it.

Investigators at Temple University (Philadelphia, PA, USA) had reported previously that 8-isoprostaneF2alpha (8ISO)—a marker for lipid oxidation and an indicator of oxidative stress—increased brain amyloid-beta levels and deposition in the Tg2576 mouse Alzheimer's disease model.

In the current study, the investigators continued this line of research by examining how (8ISO) affected behavior and tau protein metabolism. More...
To this end, they characterized the behavioral, biochemical, and neuropathologic effects of 8ISO in the triple transgenic mouse model.

They reported in the October 10, 2014, online edition of the journal Neurobiology of Aging that compared with controls, the transgenic mice receiving 8ISO showed significant memory deficits, increase in tau phosphorylation, activation of the cyclin kinase-5 pathway, and neuroinflammation. All these effects could be prevented by treatment with drugs that blocked the thromboxane receptor, a G-protein coupled receptor coupled to the G protein Gq.

“Besides the two major signature brain pathologies associated with Alzheimer’s disease, amyloid beta plaques and the tangles which are formed from the phosphorylation of the tau protein, researchers have also known for a while that there is a signature from oxidation stress,” said senior author Dr. Domenico Praticò, professor of pharmacology, microbiology, and immunology in Temple University. “But it has always been believed that oxidative stress was just a bystander and did not have an active function in the development of the disease.”

“For the first time we have identified this receptor as the culprit responsible for the bad things that happen with the disease when high levels of oxygen free radicals are produced,” said Dr. Praticò. “Basically, it sends the wrong message inside the neuronal cells, and with time, this definitely will result in all the clinical manifestations of the disease, such as cognitive impairment, loss of memory, and brain cell death. This indirectly confirmed for us that the free radicals worked through this receptor.”

Related Links:

Temple University




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.